Obstetrics/Gynecology
RSSArticles
-
Report Details Effect of Mifepristone Labeling Change
New research indicates that for Texas providers and patients, the 2016 Food and Drug Administration’s (FDA) new labeling for the abortion drug mifepristone increased access options and brought the proportion of medication abortions in the state into alignment with national data.
-
Test in Development to Detect Preterm Birth
Scientists at Brigham and Women’s Hospital have published early results of an investigative blood test designed to predict which women may be at increased risk and which ones may be at lower-than-average risk for spontaneous preterm delivery. The researchers have identified circulating microparticle proteins found in blood samples taken in the first trimester of pregnancy that may provide clues about the risk of spontaneous preterm birth.
-
National Plan Aimed at Ending HIV in the United States
The goal of a new national plan is to end the HIV epidemic in the United States.
-
HPV Immunizations Making Mark on Disease
In a multi-year analysis of cervical precancers, data indicate that the incidence of cancers caused by human papillomavirus (HPV) types 16 and 18, which have been targeted by vaccination, has declined.
-
Reproductive Health Advocates Push Back Against Proposed Title X Plans
On March 4, the Trump administration published a final regulation that is a new version of the Reagan administration’s “domestic gag rule.” With the rule’s publication in the Federal Register, a 60-day clock is ticking until provisions of the rule start going into effect.
-
Advanced Research Underway on Potential Copper IUD
Patient enrollment has begun in the United States for Phase III trials of a new copper intrauterine device (IUD) with a flexible frame.
-
The Effect of Preconception Vitamin D Levels on Live Birth and Pregnancy Loss
This secondary analysis of Effects of Aspirin in Gestation and Reproduction trial found that women with sufficient 25-hydroxyvitamin D levels (≥ 30 ng/mL) were more likely to become pregnant and have a live birth than women with insufficient concentrations of vitamin D.
-
Update on Treatments for Vulvovaginal Atrophy
Vulvovaginal atrophy, now known as the genitourinary syndrome of menopause (GSM), occurs with the decline of estrogen in the menopausal period. As with many clinical conditions, the spectrum of GSM requires the clinician to consider the effect on the patient’s quality of life. Although many symptoms are pacified effectively with situational lubricants and regular moisturizers, local estrogen is a safe, effective, and affordable way to treat the vulvovaginal changes of menopause.
-
Infertility Therapy Leads to Increased Risk of Severe Maternal Morbidity
Women undergoing infertility treatment, particularly in vitro fertilization, are at higher risk of severe maternal morbidity, but the overall risk remains low.
-
Predicting Recurrence After Pelvic Organ Prolapse Surgery
SYNOPSIS: Prediction models can provide helpful information regarding the risk of recurrence after prolapse surgery.